Rege Nephro Co Ltd: Valuation, Funding & Investors
Rege Nephro Co., Ltd. is a South Korean company specializing in the development of regenerative treatments for kidney diseases. The company is advancing clinical trials for RN-014, a promising treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and preparing for U.S. clinical trials. Additionally, Rege Nephro is completing preclinical trials for RN-032, a cell therapy product targeting Chronic Kidney Disease (CKD).
Leadership & Board
- Current Number of Employees
- 16
- Current LinkedIn Followers
- 375
Latest Estimated Valuation
- Total Amount Raised
- $15M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $15M
- Latest Funding Round
- Series B
Employee Trend
Rege Nephro Co Ltd had 16 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Rege Nephro Co Ltd had 375 followers as of November 16, 2026. The number of followers increased by 9 (2.46%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 14, 2025 | Series B | $15.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| DCI Partners Co., Ltd. | Series B |
| JIC Venture Growth Investments Co., Ltd. | Series B |
| Nippon Venture Capital CO., Ltd. | Series B |
| TOHOKU University Venture Partners Co., Ltd. | Series B |
| Golden Asia Fund Ventures Ltd. | Series B |
| Mitsui Chemicals, Inc. | Series B |
| Global Brain Corporation | Series B |
| Kyoto University Innovation Capital Co., Ltd. | Series B |
Similar Companies
A snapshot of private companies similar to Rege Nephro Co Ltd, helping you discover and navigate related company profiles.








